Source: Healio News
The FDA granted fast track designation to ALLO-605, a chimeric antigen receptor T-cell therapy for adults with relapsed or refractory multiple myeloma.
ALLO-605 (Allogene Therapeutics) is an allogeneic, gene-edited CAR T-cell therapy that targets the B-cell maturation antigen (BCMA) on the surface of cancer cells.
The therapy is derived from healthy donor-induced pluripotent stem cells and was developed using TurboCAR, Allogene’s proprietary platform based on programmable cytokine signaling that aims to improve the potency and function of CAR T cells.
The FDA’s fast track designation